Updates are available Correction dated 2025-01-31
Click to view Correction: https://doi.org/10.1038/s41586-025-08659-y
-
Authors
Fane, Mitchell E.
Chhabra, Yash
Alicea, Gretchen M.
Maranto, Devon A.
Douglass, Stephen M.
Webster, Marie R. https://orcid.org/0000-0001-7633-7150
Rebecca, Vito W.
Marino, Gloria E.
Almeida, Filipe
Ecker, Brett L.
Zabransky, Daniel J. https://orcid.org/0000-0002-8184-3346
Hüser, Laura
Beer, Thomas
Tang, Hsin-Yao https://orcid.org/0000-0003-1838-018X
Kossenkov, Andrew
Herlyn, Meenhard https://orcid.org/0000-0003-0839-0739
Speicher, David W.
Xu, Wei
Xu, Xiaowei
Jaffee, Elizabeth M. https://orcid.org/0000-0003-3841-6549
Aguirre-Ghiso, Julio A.
Weeraratna, Ashani T. https://orcid.org/0000-0003-0448-6952
- License Information
-
More Information
Article History
Received: 17 August 2020
Accepted: 19 April 2022
First Online: 1 June 2022
Change Date: 31 January 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-08659-y
Competing interests
: J.A.A.-G. is a scientific co-founder of, scientific advisory board member of, equity owner in and receives financial compensation as a consultant for HiberCell, a Mount Sinai spin-off company that is focused on therapeutics that prevent or delay the recurrence of cancer. A.T.W. is on the board of reGAIN Therapeutics. E.M.J. reports other support from Abmeta, personal fees from Genocea, personal fees from Achilles, personal fees from DragonFly, personal fees from Candel Therapeutics, other support from the Parker Institute, grants and other support from Lustgarten, personal fees from Carta, grants and other support from Genentech, grants and other support from AstroZeneca, personal fees from NextCure and grants and other support from Break Through Cancer outside of the submitted work.
